Ask AI
ProCE Banner Activity

From Pathway to Patient: Making Sense of TYK2 Inhibition in Real-world Plaque Psoriasis Decisions

Slideset

TYK2 inhibitors provide a targeted approach to plaque psoriasis by selectively modulating signaling pathways within the IL-23/IL-17 axis, a key driver of disease pathogenesis. Use these downloadable slides to gain expert insights on emerging data presented at the AAD 2026 Annual Meeting and the evolving role of TYK2 inhibition in moderate to severe plaque psoriasis. Explore how next-generation TYK2 inhibitors may offer faster and deeper responses compared with deucravacitinib and potentially reshape the treatment landscape. Consider how these findings may inform future clinical decision-making.

Released: October 26, 2026

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc.

Target Audience

This activity is intended for dermatology HCPs, including dermatologists, nurse practitioners (NPs), physician associates (PAs), and other HCPs who care for patients with PsO.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the unmet medical needs in the management of moderate to severe psoriasis, including significant under-treatment/nonadherence and its impact, comorbidities, and the need for more effective and well-tolerated treatments

  • Differentiate the efficacy, safety, and selectivity profiles of treatments targeting TYK2 versus JAK1, JAK2, and JAK3 signaling pathways in moderate to severe psoriasis

  • Summarize the recent and ongoing clinical trial data for current and emerging oral small molecule treatments for patients with moderate to severe psoriasis

  • Identify patients with psoriasis who would be appropriate candidates for oral small molecule treatment based on patient preference, efficacy, and safety